New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CTRP;SWKS;RPRX;PII;LXK From The Last 14 Days
Check below for free stories on CTRP;SWKS;RPRX;PII;LXK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 18, 2014
09:24 EDTSWKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTSWKSSkyworks price target raised to $65 from $55 at Oppenheimer
Oppenheimer increased its price target on Skyworks after the company reported stronger than expected results and guidance. The firm called the company's results and guidance "exemplary." It reiterates an Outperform rating on the shares.
08:23 EDTSWKSSkyworks price target raised to $60 from $50 at JMP Securities
Subscribe for More Information
08:01 EDTSWKSSkyworks price target raised to $55 form $51 at Canaccord
Subscribe for More Information
07:29 EDTSWKSSkyworks price target raised to $58 from $54 at Brean Capital
Subscribe for More Information
July 17, 2014
18:31 EDTSWKSOn The Fly: After Hours Movers
Subscribe for More Information
16:58 EDTSWKSSkyworks sees Q4 EPS $1.00, consensus 87c
Sees Q4 revenue $680M, consensus $608.11M.
16:56 EDTSWKSSkyworks reports Q3 EPS 83c, consensus 80c
Subscribe for More Information
15:26 EDTSWKSNotable companies reporting after market close
Subscribe for More Information
July 16, 2014
13:28 EDTRPRXRepros Therapeutics trial endpoints should be achieved, says Piper Jaffray
Piper Jaffray believes the endpoints selected for the Androxal Phase 3 studies for the treatment of secondary hypogonadism should be "readily achieved." Piper views the company's dialogue with the FDA as "very constructive" and reiterates an Overweight rating on Repros with a $26 price target.
09:26 EDTRPRXRepros Therapeutics announces FDA confirmation of endpoints for Androxal
Repros Therapeutics announced it has received additional guidance from the FDA regarding primary endpoints for the two studies, ZA-304 and ZA-305, that it is currently conducting comparing Androxal to the leading approved testosterone gel and placebo. The FDA proposed three co-primary endpoints: Percentage change from baseline in sperm concentration comparing Androxal to the leading U.S. testosterone replacement therapy; proportion of men obtaining a testosterone in the normal range; percentage of men that exhibit sperm greater than or equal to 10M/mL at the end of 16 weeks of dosing and testosterone in the normal range, comparing Androxal to a testosterone gel as well as comparing Androxal to placebo. The primary endpoints and statistical analysis plan outlined for ZA-304 and ZA-305 below are being modified to comply with the FDA suggestions. The company believes the two studies are adequately powered to meet these endpoints.
07:35 EDTPIIPolaris Industries should be bought at current levels, says Wells Fargo
After conducting checks, Wells Fargo believes that Polaris continues to gain share in off-road vehicles while making strides with its Indian motorcycle ramp. The firm keeps an Outperform rating on the stock.
July 15, 2014
10:15 EDTSWKSSkyworks expect Q3 guidance of $622M vs. consensus of $606M, says Rosenblatt
Subscribe for More Information
10:00 EDTLXKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adecogro (AGRO) downgraded to Underperform from Neutral at BofA/Merrill... Campbell Soup (CPB) downgraded to Sell from Neutral at Goldman... Credicorp (BAP) downgraded to Neutral from Overweight at JPMorgan... El Paso Pipeline (EPB) downgraded to Neutral from Buy at Citigroup... Kellogg (K) downgraded to Sell from Neutral at Goldman... Kodiak Oil & Gas (KOG) downgraded to Market Perform from Outperform at BMO Capital... Lexmark (LXK) downgraded at Bernstein... Maxim Integrated (MXIM) downgraded to Equal Weight from Overweight at Barclays... Republic Airways (RJET) downgraded to Underperform from Neutral at BofA/Merrill... Sasol (SSL) downgraded to Neutral from Buy at Citigroup... Time Warner (TWX) downgraded to Equal Weight from Overweight at Evercore.
08:06 EDTSWKSSkyworks Q4 guidance poised to beat expectations, says Oppenheimer
Subscribe for More Information
06:26 EDTLXKLexmark downgraded at Bernstein
Subscribe for More Information
06:22 EDTLXKLexmark downgraded to Underperform from Market Perform at Bernstein
July 14, 2014
09:14 EDTSWKSSemiconductor top picks at Topeka
Topeka's anticipates strong unit growth in the smartphone, tablet and wearable end markets and recommends exposure to large/mid cap growth names Intel (INTC), Skyworks (SWKS), Atmel and (ATML), small cap growth name, Rambus (RMBS), and value names Freescale (FSL), Spansion (CODE) and Silicon Motion (SIMO).
07:35 EDTLXKLexmark increases tender offer price for all outstanding shares of ReadSoft
Lexmark has increased its cash tender offer price for all of the outstanding shares of Sweden-based ReadSoft to Swedish Krona 50.00, a 16% increase from Lexmark's prior offer of SEK 43.00, for each Class A and Class B share of ReadSoft for a price of approximately $224M, net of cash acquired. Lexmark made the decision to increase its tender offer price in response to a competitive offer for ReadSoft shares announced on July 7. This cash offer by Lexmark of SEK 50.00 is 11% higher than the most recent competitive offer. Lexmark has also directly acquired shares in ReadSoft and now owns approximately 5.3% of all outstanding shares in ReadSoft. The new offer period will begin on or about August 7 and run to August 28, unless otherwise extended. Settlement of the tender offer is expected to occur around September 4, after the end of the offer period.
July 10, 2014
07:46 EDTPIIMost concerns about Polaris Industries overblown, says BMO Capital
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use